Gw Pharma ADR (GWPH) 82.70 $GWPH
Zimmer Biomet's LDR Buyout On Track, Dental Still a Pain
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:45AM CDT
On Sep 2, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
ZBH: 129.06 (+0.71), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
GNC Holdings Hit by Dismal Q2 Results, Competition Rife
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:12AM CDT
GNC Holdings (GNC) ended second-quarter 2016 on a disappointing note as its revenue figure failed to meet the Zacks Consensus Estimate.
GWPH: 82.70 (+0.42), GNC: 20.79 (-0.02), QDEL: 21.61 (-0.13), LNTH: 9.55 (+0.05)
Medtronic Posts Positive Long-term Data for Micra Pacemaker
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:00AM CDT
Medtronic's (MDT) Micra TPS also successfully reduced the risk of patient hospitalization by 47% and risk of system revisions by 82%
MDT: 87.39 (+0.41), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), LNTH: 9.55 (+0.05)
Boston Scientific's Innovation & Emerging Market Raise Hope
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:08AM CDT
On Aug 31, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
BSX: 24.18 (-0.15), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), LNTH: 9.55 (+0.05)
NuVasive: Strong Q2 Results, Overseas Holds Solid Prospect
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:13AM CDT
NuVasive (NUVA) posted strong results in the second quarter of 2016, with both earnings and revenues squarely beating the Zacks Consensus Estimate
GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), LNTH: 9.55 (+0.05), NUVA: 66.08 (+0.02)
Phibro Animal Health (PAHC) Q4 Earnings Top, Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 6:51AM CDT
Phibro's (PAHC) fiscal fourth-quarter bottom line comfortably exceeding the Zacks Consensus Estimate, while its revenues expanded in low-single-digit on a year-over-year basis.
GWPH: 82.70 (+0.42), PAHC: 25.73 (+0.14), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
Medtronic on Track with Covidien Synergy, Buys HeartWare
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 9:02AM CDT
On Aug 26, 2016, we issued an updated research report on Medtronic plc (MDT).
MDT: 87.39 (+0.41), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
Hill-Rom (HRC) Hits New 52-Week High on Solid Q3 Results
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:08AM CDT
Shares of Hill-Rom (HRC) rallied to a new 52-week high of $59.45 on Aug 26.
GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02), HRC: 59.74 (+0.49)
Medtronic (MDT) Beats Q1 Earnings, Revenues Closely In-Line
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:29PM CDT
Medtronic plc (MDT)'s reported financial results for first-quarter fiscal 2017. Adjusted earnings per share (EPS) in the reported quarter came in at $1.03, 2 cents ahead of the Zacks Consensus Estimate.
MDT: 87.39 (+0.41), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 9.2%
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:00AM CDT
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
GWPH: 82.70 (+0.42), TGTX: 6.53 (+0.02)
Will GW Pharmaceuticals (GWPH) Crush Estimates at Its Next Earnings Report?
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 8:00AM CDT
GW Pharmaceuticals has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
GWPH: 82.70 (+0.42)
Medtronic's HeartWare Takeover Complete for $1.1 Billion
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:54AM CDT
With HeartWare in its kitty, Medtronic (MDT) will now gracefully lead the global VAD market for heart failure patients.
MDT: 87.39 (+0.41), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), HTWR: 58.20 (+0.22), NUVA: 66.08 (+0.02)
Phibro Animal Health: Currency & Competition Woes Persist
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 3:33PM CDT
Phibro (PAHC) faces competition from generic alternatives of some of its products that may weigh on its future financial health and operational performance.
GWPH: 82.70 (+0.42), PAHC: 25.73 (+0.14), BAX: 46.23 (+0.05), QDEL: 21.61 (-0.13)
The Growth of the Legal and Medical Marijuana Markets
PR Newswire - Tue Aug 23, 8:57AM CDT
The legal marijuana market in the United States is projected to grow substantially in 2016. A recent report by New Frontier and ArcView Market Research projected the marijuana market in the United States to grow to $7.1 billion in 2016, which represents a 26% growth comparing to 2015. Veritas Pharma Inc. (OTC: VRTHF), Cara Therapeutics Inc (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Terra Tech Corp. (TRTC), GW Pharmaceuticals PLC (NASDAQ: GWPH)
CARA: 5.41 (+0.03), GWPH: 82.70 (+0.42), ZYNE: 8.40 (-0.17)
Illumina Rallies on Rumors of Takeover by Thermo Fisher
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:42AM CDT
Reportedly, Thermo Fisher (TMO) has made an all-stock offer of $30 billion to acquire Illumina (ILMN), which currently has a market cap of over $25 billion.
GWPH: 82.70 (+0.42), TMO: 150.82 (-0.13), QDEL: 21.61 (-0.13), ILMN: 168.40 (-0.16)
Cardiovascular Systems (CSII) Catches Eye: Stock Up 5.6%
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 7:40AM CDT
Cardiovascular Systems Inc. (CSII) saw its shares almost 6% in the last trading session.
CSII: 24.46 (+0.01), GWPH: 82.70 (+0.42)
Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.59 (+0.23), GWPH: 82.70 (+0.42), CORT: 5.32 (-0.03), PCRX: 39.32 (-1.05)
Bruker's Q2 Results Disappoint, Product Launches Continue
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:14AM CDT
On Aug 12, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR).
GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), BRKR: 22.34 (-0.10), NUVA: 66.08 (+0.02)
Phibro (PAHC) Focuses on Growth Amid Pricing Pressure
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:30AM CDT
On Aug 16, 2016, we issued an updated research report on Phibro Animal Health Corporation (PAHC).
GWPH: 82.70 (+0.42), PAHC: 25.73 (+0.14), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
Zimmer Biomet Acquires CD Diagnostics, Targets PJI Market
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:27AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) announced the buyout of CD Diagnostics, an immunoassays and biomarker testing developer.
ZBH: 129.06 (+0.71), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
Zimmer Biomet's LDR Buyout On Track, Dental Still a Pain
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:45AM CDT
On Sep 2, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
ZBH: 129.06 (+0.71), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
GNC Holdings Hit by Dismal Q2 Results, Competition Rife
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:12AM CDT
GNC Holdings (GNC) ended second-quarter 2016 on a disappointing note as its revenue figure failed to meet the Zacks Consensus Estimate.
GWPH: 82.70 (+0.42), GNC: 20.79 (-0.02), QDEL: 21.61 (-0.13), LNTH: 9.55 (+0.05)
Medtronic Posts Positive Long-term Data for Micra Pacemaker
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:00AM CDT
Medtronic's (MDT) Micra TPS also successfully reduced the risk of patient hospitalization by 47% and risk of system revisions by 82%
MDT: 87.39 (+0.41), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), LNTH: 9.55 (+0.05)
Boston Scientific's Innovation & Emerging Market Raise Hope
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:08AM CDT
On Aug 31, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
BSX: 24.18 (-0.15), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), LNTH: 9.55 (+0.05)
NuVasive: Strong Q2 Results, Overseas Holds Solid Prospect
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:13AM CDT
NuVasive (NUVA) posted strong results in the second quarter of 2016, with both earnings and revenues squarely beating the Zacks Consensus Estimate
GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), LNTH: 9.55 (+0.05), NUVA: 66.08 (+0.02)
Phibro Animal Health (PAHC) Q4 Earnings Top, Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 6:51AM CDT
Phibro's (PAHC) fiscal fourth-quarter bottom line comfortably exceeding the Zacks Consensus Estimate, while its revenues expanded in low-single-digit on a year-over-year basis.
GWPH: 82.70 (+0.42), PAHC: 25.73 (+0.14), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
Medtronic on Track with Covidien Synergy, Buys HeartWare
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 9:02AM CDT
On Aug 26, 2016, we issued an updated research report on Medtronic plc (MDT).
MDT: 87.39 (+0.41), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
Hill-Rom (HRC) Hits New 52-Week High on Solid Q3 Results
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:08AM CDT
Shares of Hill-Rom (HRC) rallied to a new 52-week high of $59.45 on Aug 26.
GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02), HRC: 59.74 (+0.49)
Medtronic (MDT) Beats Q1 Earnings, Revenues Closely In-Line
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:29PM CDT
Medtronic plc (MDT)'s reported financial results for first-quarter fiscal 2017. Adjusted earnings per share (EPS) in the reported quarter came in at $1.03, 2 cents ahead of the Zacks Consensus Estimate.
MDT: 87.39 (+0.41), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 9.2%
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:00AM CDT
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
GWPH: 82.70 (+0.42), TGTX: 6.53 (+0.02)
Will GW Pharmaceuticals (GWPH) Crush Estimates at Its Next Earnings Report?
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 8:00AM CDT
GW Pharmaceuticals has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
GWPH: 82.70 (+0.42)
Medtronic's HeartWare Takeover Complete for $1.1 Billion
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:54AM CDT
With HeartWare in its kitty, Medtronic (MDT) will now gracefully lead the global VAD market for heart failure patients.
MDT: 87.39 (+0.41), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), HTWR: 58.20 (+0.22), NUVA: 66.08 (+0.02)
Phibro Animal Health: Currency & Competition Woes Persist
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 3:33PM CDT
Phibro (PAHC) faces competition from generic alternatives of some of its products that may weigh on its future financial health and operational performance.
GWPH: 82.70 (+0.42), PAHC: 25.73 (+0.14), BAX: 46.23 (+0.05), QDEL: 21.61 (-0.13)
The Growth of the Legal and Medical Marijuana Markets
PR Newswire - Tue Aug 23, 8:57AM CDT
The legal marijuana market in the United States is projected to grow substantially in 2016. A recent report by New Frontier and ArcView Market Research projected the marijuana market in the United States to grow to $7.1 billion in 2016, which represents a 26% growth comparing to 2015. Veritas Pharma Inc. (OTC: VRTHF), Cara Therapeutics Inc (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Terra Tech Corp. (TRTC), GW Pharmaceuticals PLC (NASDAQ: GWPH)
CARA: 5.41 (+0.03), GWPH: 82.70 (+0.42), ZYNE: 8.40 (-0.17)
Illumina Rallies on Rumors of Takeover by Thermo Fisher
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:42AM CDT
Reportedly, Thermo Fisher (TMO) has made an all-stock offer of $30 billion to acquire Illumina (ILMN), which currently has a market cap of over $25 billion.
GWPH: 82.70 (+0.42), TMO: 150.82 (-0.13), QDEL: 21.61 (-0.13), ILMN: 168.40 (-0.16)
Cardiovascular Systems (CSII) Catches Eye: Stock Up 5.6%
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 7:40AM CDT
Cardiovascular Systems Inc. (CSII) saw its shares almost 6% in the last trading session.
CSII: 24.46 (+0.01), GWPH: 82.70 (+0.42)
Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.59 (+0.23), GWPH: 82.70 (+0.42), CORT: 5.32 (-0.03), PCRX: 39.32 (-1.05)
Bruker's Q2 Results Disappoint, Product Launches Continue
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:14AM CDT
On Aug 12, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR).
GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), BRKR: 22.34 (-0.10), NUVA: 66.08 (+0.02)
Phibro (PAHC) Focuses on Growth Amid Pricing Pressure
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:30AM CDT
On Aug 16, 2016, we issued an updated research report on Phibro Animal Health Corporation (PAHC).
GWPH: 82.70 (+0.42), PAHC: 25.73 (+0.14), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
Zimmer Biomet Acquires CD Diagnostics, Targets PJI Market
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 9:27AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) announced the buyout of CD Diagnostics, an immunoassays and biomarker testing developer.
ZBH: 129.06 (+0.71), GWPH: 82.70 (+0.42), QDEL: 21.61 (-0.13), NUVA: 66.08 (+0.02)
